Background Gay and bisexual men (GBM) are a key population affected by human
immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection. We aimed to measure …

Abstract Background Modeling of the London hepatitis C virus (HCV) epidemic in men who
have sex with men (MSM) and are living with human immunodeficiency virus (HIV) …

Background Microelimination of hepatitis C virus (HCV) among people living with human
immunodeficiency virus (HIV) may be feasible in Australia, given unrestricted access to …

Background Among the 1.2 million people with human immunodeficiency virus (HIV) in the
United States, 25% are coinfected with hepatitis C virus (HCV). The availability of effective …

Background Among the 1.2 million people with human immunodeficiency virus (HIV) in the
United States, 25% are coinfected with hepatitis C virus (HCV). The availability of effective …

Abstract Background In 2016, the World Health Organization (WHO) introduced global
targets for the elimination of hepatitis C virus (HCV) by 2030. We conducted a nationwide …

Background The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA)
led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency …

Background Human immunodeficiency virus (HIV)–positive gay and bisexual men (GBM) in
Australia are well engaged in care. The World Health Organization's (WHO) hepatitis C virus …

To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to
implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017 …

Abstract Background The Swiss HCVree Trial (NCT 02785666) was conducted in 2015–
2017 with the goal of implementing a population-based systematic hepatitis C virus (HCV) …